169 related articles for article (PubMed ID: 32685589)
1. High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study.
Kanter J; Bhor M; Li X; Li FY; Paulose J
J Health Econ Outcomes Res; 2019; 6(3):174-184. PubMed ID: 32685589
[TBL] [Abstract][Full Text] [Related]
2. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
Udeze C; Evans KA; Yang Y; Lillehaugen T; Manjelievskaia J; Mujumdar U; Li N; Andemariam B
Adv Ther; 2023 Aug; 40(8):3543-3558. PubMed ID: 37332020
[TBL] [Abstract][Full Text] [Related]
3. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study.
Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 36873574
[No Abstract] [Full Text] [Related]
4. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.
Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 32685602
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
Marfo K; Dei-Adomakoh Y; Segbefia C; Dwomoh D; Edgal A; Ampah N; Ramachandrachar BC; Subramanyam K; Natarajan A; Egbujo O; Ataga KI
BMC Health Serv Res; 2023 Sep; 23(1):1018. PubMed ID: 37735428
[TBL] [Abstract][Full Text] [Related]
6. Sickle cell disease complications: Prevalence and resource utilization.
Shah N; Bhor M; Xie L; Paulose J; Yuce H
PLoS One; 2019; 14(7):e0214355. PubMed ID: 31276525
[TBL] [Abstract][Full Text] [Related]
7. Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study.
Shah N; Bhor M; Xie L; Paulose J; Yuce H
J Health Econ Outcomes Res; 2020; 7(1):52-60. PubMed ID: 32685598
[TBL] [Abstract][Full Text] [Related]
8. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
Shah NR; Bhor M; Latremouille-Viau D; Kumar Sharma V; Puckrein GA; Gagnon-Sanschagrin P; Khare A; Kumar Singh M; Serra E; Davidson M; Xu L; Guerin A
J Med Econ; 2020 Nov; 23(11):1345-1355. PubMed ID: 32815766
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Vaso-occlusive Crises in United States Sickle Cell Disease Patients: A Retrospective Claims-based Study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
J Health Econ Outcomes Res; 2019; 6(3):106-117. PubMed ID: 32685584
[TBL] [Abstract][Full Text] [Related]
10. Impact of Hydroxyurea Therapy in Reducing Pain Crises, Hospital Admissions, and Length of Stay Among Sickle Cell Patients in the Eastern Region of Saudi Arabia.
Albohassan H; Ammen M; Alomran AA; Bu Shehab H; Al Sakkak H; Al Bohassan A
Cureus; 2022 Nov; 14(11):e31527. PubMed ID: 36540486
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries.
Desai RJ; Mahesri M; Globe D; Mutebi A; Bohn R; Achebe M; Levin R; Schneeweiss S
Ann Hematol; 2020 Nov; 99(11):2497-2505. PubMed ID: 32869184
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis.
Gallagher ME; Chawla A; Brady BL; Badawy SM
J Med Econ; 2022; 25(1):1140-1148. PubMed ID: 36222016
[TBL] [Abstract][Full Text] [Related]
13. Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
Olson AL; Hartmann N; Patnaik P; Garry EM; Bohn RL; Singer D; Baldwin M; Wallace L
Adv Ther; 2022 Apr; 39(4):1794-1809. PubMed ID: 35199282
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults.
Cooper TE; Hambleton IR; Ballas SK; Johnston BA; Wiffen PJ
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742673
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource utilization and costs 2 years pre- and post-lumbar spine surgery for stenosis: a national claims cohort study of 22,182 cases.
Koltsov JCB; Sambare TD; Alamin TF; Wood KB; Cheng I; Hu SS
Spine J; 2022 Jun; 22(6):965-974. PubMed ID: 35123048
[TBL] [Abstract][Full Text] [Related]
16. Transition to adult care in sickle cell disease: A longitudinal study of clinical characteristics and disease severity.
Kayle M; Docherty SL; Sloane R; Tanabe P; Maslow G; Pan W; Shah N
Pediatr Blood Cancer; 2019 Jan; 66(1):e27463. PubMed ID: 30251318
[TBL] [Abstract][Full Text] [Related]
17. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
[TBL] [Abstract][Full Text] [Related]
18. Healthcare costs and resource utilization in patients with severe aplastic anemia in the US.
Cai B; Said Q; Li X; Li FY; Arcona S
J Med Econ; 2019 Oct; 22(10):1055-1062. PubMed ID: 31296074
[No Abstract] [Full Text] [Related]
19. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
Kang HA; Barner JC; Lawson KA; Rascati K; Mignacca RC
Am J Hematol; 2023 Jan; 98(1):90-101. PubMed ID: 36251408
[TBL] [Abstract][Full Text] [Related]
20. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
